Acute Respiratory Distress Syndrome (ARDS) is a potentially life-threatening condition characterized by rigid, non-compliant lungs and inadequate oxygenation. This condition presents as an acute, widespread inflammatory lung injury that can affect critically ill patients. The primary approach to treating ARDS involves employing mechanical ventilation with low tidal volumes and positive end-expiratory pressure (PEEP) to support oxygen levels and minimize further lung damage.
The key facets of dealing with Acute Respiratory Distress Syndrome (ARDS) pertain to its diagnosis and treatment. Diagnosis encompasses the process of distinguishing this condition from other potential disorders and delineating its characteristics. The diagnosis of ARDS typically relies on a physical examination, chest X-ray, and oxygenation levels. ARDS can be triggered by various factors such as COVID-19 (COVID-19 Disease 2019), sepsis, exposure to harmful substances, severe pneumonia, among others, with its severity ranging from mild to moderate and severe. The primary recipients of ARDS-related services include hospitals, clinics, ambulatory service centers, and other healthcare facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The acute respiratory distress syndrome (ARDS) market research report is one of a series of new reports from The Business Research Company that provides acute respiratory distress syndrome (ARDS) market statistics, including acute respiratory distress syndrome (ARDS) industry global market size, regional shares, competitors with an acute respiratory distress syndrome (ARDS) market share, detailed acute respiratory distress syndrome (ARDS) market segments, market trends and opportunities and any further data you may need to thrive in the acute respiratory distress syndrome (ARDS) industry. This acute respiratory distress syndrome (ARDS) market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The acute respiratory distress syndrome (ards) market size has grown strongly in recent years. It will grow from $1.29 billion in 2024 to $1.41 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to advancements in critical care medicine, aging population, pulmonary rehabilitation, multidisciplinary care teams.
The acute respiratory distress syndrome (ards) market size is expected to see rapid growth in the next few years. It will grow to $2.15 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to global healthcare preparedness, vaccine development and infectious disease management, telemedicine and remote monitoring, patient-centered care models. Major trends in the forecast period include artificial lung devices, personalized ventilation strategies, lung protective ventilation, drug therapies for ards subtypes.
The forecast of 11.1% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to advanced extracorporeal membrane oxygenation (ECMO) components and lung-protective ventilator modules imported from Italy and South Korea, potentially compromising life-saving interventions and increasing ICU operational burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of pneumonia is expected to drive the growth of the acute respiratory distress syndrome (ARDS) market. Pneumonia is an infection that affects one or both lungs, leading to the accumulation of fluid or pus in the alveoli, or air sacs of the lungs. This causes an inflammatory reaction that increases blood vessel permeability, allowing fluid to leak into the alveoli and impairing the exchange of oxygen and carbon dioxide, resulting in respiratory distress. For example, in November 2023, the Centre for Tropical Medicine and Global Health, a UK-based leader in healthcare research, reported a significant rise in pneumonia cases in Kenya, which increased from 477,186 in 2020-2021 to 793,864 in 2022-2023. As a result, the growing prevalence of pneumonia is driving the expansion of the ARDS market.
The rising incidence of respiratory illnesses is expected to drive the growth of the acute respiratory distress syndrome (ARDS) market. Respiratory illnesses encompass a range of medical conditions that affect the airways and lungs, often causing difficulty in breathing. The increasing number of respiratory illnesses, including COVID-19, is a significant factor contributing to the growth of the ARDS market. As more individuals develop respiratory conditions, the demand for ARDS treatments and therapies is likely to rise, boosting market expansion. For instance, in November 2023, the Bureau of Labor Statistics, a US-based government agency, reported that in 2022, the illness rate among private industry employers increased to 45.2 cases per 10,000 full-time equivalent (FTE) workers, up from 37.7 cases in 2021. This increase was largely attributed to a rise in respiratory illnesses, which jumped from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Therefore, the growing number of respiratory illnesses is driving the expansion of the ARDS market.
Prominent companies operating within the acute respiratory distress syndrome (ARDS) market are dedicating their efforts to the creation of groundbreaking drugs and supplements, including Aviptadil and HSP90 inhibitors, aimed at reinforcing their market position. Aviptadil, a synthetic vasoactive intestinal peptide (VIP), is designed to specifically target receptors on lung alveolar type II cells. For instance, in November 2022, Zuventus Healthcare Ltd., an Indian pharmaceutical manufacturing company, introduced Aviptadil as a treatment for acute respiratory distress syndrome. Aviptadil, functioning as a vasoactive intestinal peptide supplement, enhances breathing and reduces mortality in ARDS patients. This is achieved through Aviptadil's capacity to safeguard and regenerate Type-2 Pneumocytes, restore Type-1 Pneumocytes, increase surfactant synthesis, and suppress interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).
In January 2022, AcelRx Pharmaceuticals Inc., a specialized pharmaceutical company based in the United States, acquired Lowell Therapeutics Inc. for $32.5 million. This strategic acquisition empowers AcelRx Pharmaceuticals to expand its product portfolio and solidify its standing in the pharmaceutical industry. Lowell Therapeutics Inc., also based in the U.S., is a pharmaceutical company dedicated to developing products for the treatment of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC).
Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Drager Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.
North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the acute respiratory distress syndrome (ARDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The acute respiratory distress syndrome (ARDS) market includes revenues earned by entities by providing resolution and recovery services, medication, supplemental oxygen and mechanical ventilation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute respiratory distress syndrome (ARDS) market consists of sales of neuromuscular blockers, corticosteroids, monitoring devices, diagnostic devices and therapeutic devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acute respiratory distress syndrome (ards) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for acute respiratory distress syndrome (ards) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The acute respiratory distress syndrome (ards) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Diagnosis; Treatment
- 2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes
- 3) By Severity: Mild; Moderate; Severe
- 4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users
- Subsegments:
- 1) By Diagnosis: Imaging Tests; Blood Tests; Lung Function Tests; Other Diagnostic Methods
- 2) By Treatment: Mechanical Ventilation; Medications; Extracorporeal Membrane Oxygenation (ECMO); Supportive Care; Other Treatment Options
- Companies Mentioned: Johnson & Johnson Services Inc.; Novartis AG; GlaxoSmithKline plc; Medtronic plc; Boehringer Ingelheim International GmbH; Gilead Sciences Inc.; Amgen Inc.; Fresenius SE & Co. KGaA; Koninklijke Philips N.V.; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; CSL Behring; Terumo Corporation; ResMed Inc.; Smiths Medical Inc.; Drager Safety AG & Co. KGaA.; Getinge AB; Mallinckrodt plc; Masimo Corporation; United Therapeutics Corporation; Fisher & Paykel Healthcare Corporation Limited; Hamilton Medical AG; Zuventus Healthcare Ltd.; Windtree Therapeutics Inc.; Faron Pharmaceuticals Oy; AcelRx Pharmaceuticals Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Acute Respiratory Distress Syndrome (ARDS) Market Characteristics
3. Acute Respiratory Distress Syndrome (ARDS) Market Trends And Strategies
4. Acute Respiratory Distress Syndrome (ARDS) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Acute Respiratory Distress Syndrome (ARDS) Growth Analysis And Strategic Analysis Framework
- 5.1. Global Acute Respiratory Distress Syndrome (ARDS) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Acute Respiratory Distress Syndrome (ARDS) Market Growth Rate Analysis
- 5.4. Global Acute Respiratory Distress Syndrome (ARDS) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Acute Respiratory Distress Syndrome (ARDS) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Acute Respiratory Distress Syndrome (ARDS) Total Addressable Market (TAM)
6. Acute Respiratory Distress Syndrome (ARDS) Market Segmentation
- 6.1. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Diagnosis
- Treatment
- 6.2. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- COVID-19 Disease 2019 (COVID-19)
- Sepsis
- Inhalation Of Harmful Substances
- Severe Pneumonia
- Other Causes
- 6.3. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Mild
- Moderate
- Severe
- 6.4. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Ambulatory Service Centers
- Other End Users
- 6.5. Global Acute Respiratory Distress Syndrome (ARDS) Market, Sub-Segmentation Of Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Imaging Tests
- Blood Tests
- Lung Function Tests
- Other Diagnostic Methods
- 6.6. Global Acute Respiratory Distress Syndrome (ARDS) Market, Sub-Segmentation Of Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Mechanical Ventilation
- Medications
- Extracorporeal Membrane Oxygenation (ECMO)
- Supportive Care
- Other Treatment Options
7. Acute Respiratory Distress Syndrome (ARDS) Market Regional And Country Analysis
- 7.1. Global Acute Respiratory Distress Syndrome (ARDS) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Acute Respiratory Distress Syndrome (ARDS) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market
- 8.1. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Acute Respiratory Distress Syndrome (ARDS) Market
- 9.1. China Acute Respiratory Distress Syndrome (ARDS) Market Overview
- 9.2. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Acute Respiratory Distress Syndrome (ARDS) Market
- 10.1. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Acute Respiratory Distress Syndrome (ARDS) Market
- 11.1. Japan Acute Respiratory Distress Syndrome (ARDS) Market Overview
- 11.2. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Acute Respiratory Distress Syndrome (ARDS) Market
- 12.1. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market
- 13.1. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Acute Respiratory Distress Syndrome (ARDS) Market
- 14.1. South Korea Acute Respiratory Distress Syndrome (ARDS) Market Overview
- 14.2. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market
- 15.1. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market Overview
- 15.2. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Acute Respiratory Distress Syndrome (ARDS) Market
- 16.1. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Acute Respiratory Distress Syndrome (ARDS) Market
- 17.1. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Acute Respiratory Distress Syndrome (ARDS) Market
- 18.1. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Acute Respiratory Distress Syndrome (ARDS) Market
- 19.1. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Acute Respiratory Distress Syndrome (ARDS) Market
- 20.1. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market
- 21.1. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market Overview
- 21.2. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Acute Respiratory Distress Syndrome (ARDS) Market
- 22.1. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Acute Respiratory Distress Syndrome (ARDS) Market
- 23.1. North America Acute Respiratory Distress Syndrome (ARDS) Market Overview
- 23.2. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Acute Respiratory Distress Syndrome (ARDS) Market
- 24.1. USA Acute Respiratory Distress Syndrome (ARDS) Market Overview
- 24.2. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Acute Respiratory Distress Syndrome (ARDS) Market
- 25.1. Canada Acute Respiratory Distress Syndrome (ARDS) Market Overview
- 25.2. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Acute Respiratory Distress Syndrome (ARDS) Market
- 26.1. South America Acute Respiratory Distress Syndrome (ARDS) Market Overview
- 26.2. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Acute Respiratory Distress Syndrome (ARDS) Market
- 27.1. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Acute Respiratory Distress Syndrome (ARDS) Market
- 28.1. Middle East Acute Respiratory Distress Syndrome (ARDS) Market Overview
- 28.2. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Acute Respiratory Distress Syndrome (ARDS) Market
- 29.1. Africa Acute Respiratory Distress Syndrome (ARDS) Market Overview
- 29.2. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Acute Respiratory Distress Syndrome (ARDS) Market Competitive Landscape And Company Profiles
- 30.1. Acute Respiratory Distress Syndrome (ARDS) Market Competitive Landscape
- 30.2. Acute Respiratory Distress Syndrome (ARDS) Market Company Profiles
- 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
31. Acute Respiratory Distress Syndrome (ARDS) Market Other Major And Innovative Companies
- 31.1. Gilead Sciences Inc.
- 31.2. Amgen Inc.
- 31.3. Fresenius SE & Co. KGaA
- 31.4. Koninklijke Philips N.V.
- 31.5. Baxter International Inc.
- 31.6. Teva Pharmaceutical Industries Ltd.
- 31.7. CSL Behring
- 31.8. Terumo Corporation
- 31.9. ResMed Inc.
- 31.10. Smiths Medical Inc.
- 31.11. Drager Safety AG & Co. KGaA.
- 31.12. Getinge AB
- 31.13. Mallinckrodt plc
- 31.14. Masimo Corporation
- 31.15. United Therapeutics Corporation
32. Global Acute Respiratory Distress Syndrome (ARDS) Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Acute Respiratory Distress Syndrome (ARDS) Market
34. Recent Developments In The Acute Respiratory Distress Syndrome (ARDS) Market
35. Acute Respiratory Distress Syndrome (ARDS) Market High Potential Countries, Segments and Strategies
- 35.1 Acute Respiratory Distress Syndrome (ARDS) Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Acute Respiratory Distress Syndrome (ARDS) Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Acute Respiratory Distress Syndrome (ARDS) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
